Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Secretary McClellan?

This article was originally published in The Gray Sheet

Executive Summary

Tommy Thompson will step down from the HHS secretary spot Feb. 4 or when a successor is named, he announces Dec. 3. CMS Administrator Mark McClellan, MD/PhD, and HHS Deputy Secretary Claude Allen, JD, are considered leading contenders to replace him. Thompson also mentioned CDC Director Julie Gerberding, MD/MPH; NIH Director Elias Zerhouni, MD; and National Institute of Allergy & Infectious Diseases DirectorAnthony Fauci, MD, as possible successors. The search has moved outside the department, with some state governors reportedly interviewed; former Speaker of the House Newt Gingrich also has voiced interest. Although not discounting a future role in public service, Thompson said that after 38 years he is ready to enter the private sector. He lauded HHS' work on the Medicare Modernization Act, while conceding he "would like to have had the opportunity to negotiate" its details...

Related Content

UsernamePublicRestriction

Register

MT021272

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel